POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
January 29, 2014 18:31 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the...
New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products
November 24, 2013 19:16 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a...
SCRIP Award to Mesoblast Recognizes Strategic Importance of '2013 Financing Deal of the Year'
November 22, 2013 06:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 22, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) announced that it was today awarded the 'Financing Deal...
Mesoblast's Mesenchymal Precursor Cells Induce Functional Recovery in Ischemic Stroke Model
November 11, 2013 06:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced positive preclinical trial results which...
MESOBLAST UPDATES MARKET ON REGISTRATION PLANS FOR GVHD CELL PRODUCT IN JAPAN
October 28, 2013 01:11 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today updated the market on product registration plans in...
Mesoblast, Intrexon and ZIOPHARM to Target Cancers
October 23, 2013 18:28 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB), a world leader in the development of cell-based biologic products, Intrexon Corporation (NYSE: XON),...
Mesoblast Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy
June 25, 2013 21:12 ET
|
Mesoblast
NEW YORK, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Key Points:∙ Mesoblast has received ethics approvals to begin a clinical trial of its proprietary allogeneic, or “off-the-shelf”,...
Key Mesenchymal Precursor Cell Patent Granted in Japan
June 04, 2013 20:47 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 4, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the...
MESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR
April 22, 2013 04:07 ET
|
Mesoblast
Mesoblast's Phase 2 trial of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs has now completed six-month follow-up for all 100...
Mesoblast Completes A$170m Private Placement
March 13, 2013 23:08 ET
|
Mesoblast
MELBOURNE, Australia, March 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has completed a private placement of its...